Tuesday, December 23, 2014

Options in Metastatic Her-2 positive Breast cancer

1.Pertuzumab + Herceptin + Taxanes

2.Adotrastuzumab EMTANSINE  "a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate). Emtansine refers to the MCC-DM1 complex." (DRUG)


4."Data from five posters presented during the 2014 San Antonio Breast Cancer Symposium (SABCS) provide further evidence on the efficacy, safety and quality of life profile of eribulin, in the treatment of patients with locally advanced or metastatic breast cancer (MBC) and data in early stage breast cancer.

A second Phase 2, multicentre, open-label study, explores the feasibility of eribulin plus capecitabine as an adjuvant therapy in women with early-stage, estrogen receptor (ER) positive breast cancer." (drug)
Post a Comment